BTIG Reiterates Buy Rating on Lucid Diagnostics with $2.00 Price Target

Lucid Diagnostics (LUCD) has received a Buy rating and $2.00 price target from BTIG analyst Mark Massaro. The company's shares closed at $0.99. The analyst consensus on Lucid Diagnostics is a Strong Buy with an average price target of $3.25, a 227.06% upside from current levels. Corporate insider sentiment is positive, with 7 insiders buying shares over the past quarter.

Lucid Diagnostics Inc. (LUCD), a commercial-stage cancer prevention medical diagnostics company, has received a positive analyst rating from BTIG analyst Mark Massaro. The analyst has assigned a Buy rating to the company's shares, with a $2.00 price target. This rating aligns with the strong Buy consensus among analysts, who have an average price target of $3.25, representing a 227.06% upside from the current share price of $0.99 [2].

The positive analyst sentiment is backed by corporate insider activity, with seven insiders buying shares over the past quarter. This indicates a positive outlook among insiders, who are typically well-informed about the company's prospects.

Lucid Diagnostics has been making significant strides in its business operations and financial performance. In the second quarter of 2025, the company processed 2,756 EsoGuard® tests, recognized revenue of $1.2 million, and ended the quarter with over $30 million in proforma cash. The company is also extending its runway well past upcoming reimbursement milestones [1].

Additionally, Lucid Diagnostics is set to participate in an upcoming Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting on Medicare Local Coverage Determination (LCD) for its EsoGuard product. The meeting, scheduled for September 4, 2025, is a significant milestone that could lead to positive Medicare coverage for the product [1].

The company's stock has been performing well, with shares closing at $0.99. The positive analyst rating and insider buying activity suggest that investors may find Lucid Diagnostics an attractive investment opportunity.

References:
[1] https://stockanalysis.com/stocks/lucd/
[2] https://www.biospace.com/press-releases/lucid-diagnostics-provides-business-update-and-reports-second-quarter-2025-financial-results